Showing results (161-170 of 279) with videos related to
Sort By:
Pageof 28
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2012
Identifying and targeting ROS1 gene fusions in non-small cell lung cancerKurtis D Davies, Anh T Le, Mariana F Theodoro, et al.Cancer|February 7, 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibKaren L Reckamp, Giuseppe Giaccone, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.Lung Cancer (Amsterdam, Netherlands)|November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancerDavid E Gerber, D Ross Camidge, Daniel Morgensztern, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.Cancer Medicine|December 11, 2019
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcomaVictor M Villalobos, Gary Mo, Mark Agulnik, et al.Pageof 28